Archive
Open Access DOI:10.23937/2469-5726/1510032
Julie Azais, Pascale Vergne-Salle, Christine Bonnet, Carine Dufauret-Lombard, Richard Treves and Philippe Bertin
Article Type: Research Article | First Published: March 31, 2016
Tumour-necrosis-factor (TNF) inhibitors, used to treat rheumatoid arthritis (RA), have non-specific (placebo effect) and specific effects. This meta-analysis appraises these effects within the first 3 months of treatment. Data were collected from ACR 20, 50 and 70 scores at week-24 from RA patients receiving TNF-blockers or a placebo after methotrexate (MTX) failure....
Article Formats
- Full Article
Open Access DOI:10.23937/2469-5726/1510031
Annie HN Law and SI Yeo
Article Type: Case Report | First Published: February 07, 2016
Erdheim-Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis, with multifaceted clinical presentations. There are currently fewer than 550 cases reported in the literature. This case illustrates the protean manifestations of ECD with multisystem involvement, including skeletal and extra skeletal (cutaneous, cardiac, pituitary, retroperitoneal, and pulmonary) manifestations...
Article Formats
- Full Article
Open Access DOI:10.23937/2469-5726/1510030
Walter Berg, Ingo H Tarner, Gabriela Riemekasten, Ulf Muller-Ladner and Uwe Lange
Article Type: Research Article | First Published: January 26, 2016
Systemic sclerosis (SSc) is a chronic, severe connective tissue disorder characterized by a microangiopathy and excess deposition of connective tissue matrix in the skin and internal organs. Skin involvement is the most conspicuous manifestation of SSc, and based on its extent two distinct disease subsets are recognized, diffuse cutaneous (dcSSc) and limited cutaneous systemic sclerosis (lcSSc), with lcSSc affecting only the distal extremities and the face and dcSSc also affecting the proximal e...
Article Formats
- Full Article
Open Access DOI:10.23937/2469-5726/1510029
Thais Muniz Montalvao, Ana Luisa Miranda-Vilela, Cesar Koppe Grisolia and Leopoldo Luiz Santos-Neto
Article Type: Case Series | First Published: January 09, 2016
Systemic lupus erythematosus (SLE) is a chronic inflammatory, complex, multisystem autoimmune disease of multifactorial origin. It is characterized by a large set of antibodies, especially antinuclear antibodies. Its incidence rate varies from 1 to 10 per 100,000 persons/year and its prevalence rate is 20-70 per 100,000. It is a more frequent rare disease in women between 15 and 45 years old. The cause of SLE is still unknown; however, there is a loss of the regulatory mechanisms which maintain ...
Article Formats
- Full Article
Volume 2
Issue 1
Issue 1